From a University spin-out with its first Nature paper to the leading pharmatech innovator at the forefront of AI drug discovery, Exscientia’s journey has been all about breaking new ground to delivering exceptional results.
A snapshot of our key milestones is below.
Exscientia is founded as a spin-out from the University of Dundee
Sep: Exscientia partners with Sumitomo Dainippon Pharma - Central Nervous System
Nov: Exscientia partners with Sunovion Pharmaceuticals - Psychiatric disorders
Sep: Exscientia delivers first candidate for Sumitomo
Apr: Exscientia partners with Evotec - Immuno-oncology
May: Exscientia signs a strategic research collaboration and licence option agreement with Sanofi - Metabolic diseases
Jul: Exscientia partners with GlaxoSmithKline - Multiple therapeutic areas
Sep: Evotec invests €15 M in Exscientia
Dec: Exscientia opens Oxford office
Nov: Exscientia acquires biophysics specialists Kinetic Discovery
Nov: Exscientia establishes new Headquarters at the Oxford Science Park
Jan: Exscientia raises $26 million in Series B financing round
Jan: Exscientia partners with Roche
Mar: Exscientia expansion with subsidiary in Osaka, Japan
Mar: Exscientia partners with Celgene - Oncology and Autoimmunity
Apr: Exscientia delivers first major milestone in GSK collaboration
Jun: Exscientia partners with GT Apeiron Therapeutics - Oncology
Jul: Exscientia partners with Rallybio - Rare diseases
Aug: Sanofi exercises option to progress an innovative Bispecific small molecule project